Xin Lang Cai Jing·2025-12-15 01:53Group 1 - The core viewpoint of the news is that Junshi Biosciences has shown a stock price increase of 36.59% year-to-date, with a recent rise of 2.05% in intraday trading, reflecting positive market sentiment [1][2] - As of December 15, the stock price reached 37.33 CNY per share, with a market capitalization of 38.33 billion CNY and a trading volume of 61.95 million CNY [1] - The company reported a net inflow of 3.39 million CNY from main funds, with significant buying activity accounting for 17.39% of total trades [1] Group 2 - Junshi Biosciences, established on December 27, 2012, specializes in the research and commercialization of monoclonal antibody drugs and other therapeutic protein drugs, with 90.67% of its revenue coming from drug sales [2] - The company operates within the pharmaceutical and biotechnology sector, specifically in the biopharmaceuticals category, and is involved in precision medicine and innovative drugs [2] - For the period from January to September 2025, Junshi Biosciences achieved a revenue of 1.806 billion CNY, representing a year-on-year growth of 42.06%, while the net profit attributable to shareholders was -596 million CNY, a 35.72% increase [2] Group 3 - As of September 30, 2025, the number of shareholders for Junshi Biosciences increased by 15.17% to 35,900, while the average circulating shares per person decreased by 12.96% to 21,361 shares [2] - Among the top ten circulating shareholders, E Fund's STAR 50 ETF holds 19.39 million shares, a decrease of 2.82 million shares from the previous period [3] - Another significant shareholder, Huaxia's STAR 50 ETF, holds 18.97 million shares, down by 1.07 million shares compared to the last reporting period [3]